Immunohistochemical evaluation of somatostatin receptor subtypes in surgical pathology specimens of neuroendocrine tumors;Immunhistochemische Beurteilung von Somatostatinrezeptor-subtypen im Entnahmematerial neuroendokriner Tumoren

Pathologe

Volumn 31, Issue SUPPL. 2, 2010, Pages 199-203

  Sasano, H ^a   Iida, S ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunohistochemistry; Neuroendocrine tumors; Pathology; Receptors somatostatin; Somatostatin analogue

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ARTICLE; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; PATHOLOGY; PREDICTIVE VALUE;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMORS; PREDICTIVE VALUE OF TESTS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 79953202924     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-010-1369-z     Document Type: Article

References (14)

1. Ono K, Suzuki T, Miki Y et al (2007) Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogues SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res 27:2231-2240
2. Srirajaskanthan R, Watkins J, Marelli L et al (2009) Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies. Neuroendocrinology 89:308-314
3. Taniyama Y, Suzuki T, Mikami Y et al (2005) Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 52:605-611
4. Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198
5. Guillermet-Guibert J, Lahalou H, Pyronnet S et al (2005) Somatostain receptors as tools for diagnostic and therapy: molecular aspects. Best Pract Res Gastroenterol 19:535-551
6. Kloppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014:13-27
7. Reubi JC, Krennning E, Labmerts SW et al (1992) In vitro detection of somatostatin receptors in human tumors. Metabolism 41:104-110
8. Caplin ME, Buscombe JR, Hilson AJ et al (1998) Carcinoid syndrome. Lancet 352:799-805
9. Khasraw M, Townsend A, Price T et al (2010) Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumors. Intern Med 40:453-458
10. Oberg K (2010) Caner: antitumor effects of octoreotide LAR, a somatostatin analog, Nat Rev Endocrinol 6:188-199
11. Krenning EP, Valkema R, Kwekkeboom DJ et al (1995) Somatostatin receptor scintigraphy. In: Freman LM (ed) Nuclear Medicine Annual. Raven, New York, p 1-50
12. Papotti M, Bongiovanni M, Volante M et al (2002) Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461-475
13. Papotti M, Croce S, Bello M et al (2001) Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 439:787-797
14. Volante M, Brizzi MP, Faggiano A et al (2007) Somatostain receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172-1182